Insider Selling: Bristol-Myers Squibb Co (NYSE:BMY) EVP Sells 25,000 Shares of Stock
Bristol-Myers Squibb Co (NYSE:BMY) EVP Louis S. Schmukler sold 25,000 shares of the company’s stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $62.68, for a total value of $1,567,000.00. Following the transaction, the executive vice president now directly owns 26,777 shares in the company, valued at approximately $1,678,382.36. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
Shares of Bristol-Myers Squibb stock opened at $60.79 on Friday. The company has a current ratio of 1.66, a quick ratio of 1.51 and a debt-to-equity ratio of 0.86. The firm has a market capitalization of $138.34 billion, a PE ratio of 75.05, a price-to-earnings-growth ratio of 1.21 and a beta of 0.74. The business’s 50-day moving average price is $60.48 and its 200-day moving average price is $60.71. Bristol-Myers Squibb Co has a 12 month low of $42.48 and a 12 month high of $68.34.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $1.72 EPS for the quarter, beating the consensus estimate of $1.49 by $0.23. The firm had revenue of $10.78 billion for the quarter, compared to analyst estimates of $10.04 billion. Bristol-Myers Squibb had a return on equity of 30.06% and a net margin of 3.08%. The company’s revenue was up 82.1% on a year-over-year basis. During the same period in the prior year, the company earned $1.10 EPS. As a group, analysts predict that Bristol-Myers Squibb Co will post 6.15 earnings per share for the current fiscal year.
Institutional investors have recently made changes to their positions in the company. Stonebridge Financial Planning Group LLC bought a new position in Bristol-Myers Squibb during the 4th quarter worth approximately $26,000. grace capital bought a new position in Bristol-Myers Squibb during the 4th quarter worth approximately $26,000. Birch Capital Management LLC bought a new position in Bristol-Myers Squibb during the 4th quarter worth approximately $28,000. JCIC Asset Management Inc. bought a new position in Bristol-Myers Squibb during the 1st quarter worth approximately $25,000. Finally, Perennial Advisors LLC bought a new position in Bristol-Myers Squibb during the 1st quarter worth approximately $27,000. Hedge funds and other institutional investors own 76.51% of the company’s stock.
A number of research analysts have recently commented on BMY shares. Societe Generale cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $50.00 price target on the stock. in a research report on Monday, March 23rd. TheStreet cut Bristol-Myers Squibb from a “b-” rating to a “c+” rating in a research report on Monday, April 13th. ValuEngine cut Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a report on Wednesday, April 29th. Cfra increased their price objective on Bristol-Myers Squibb from $69.00 to $70.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Finally, Bank of America reissued a “buy” rating and set a $80.00 price objective on shares of Bristol-Myers Squibb in a report on Friday, May 15th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and twelve have issued a buy rating to the company. Bristol-Myers Squibb has a consensus rating of “Buy” and a consensus target price of $65.38.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Read More: Stock Split
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.